105355-30-4

Upstream product

• 85583-37-5 4-[2-(5-methyl-pyridin-2-yl)ethoxy]aniline 
• 292638-85-8 acrylic acid methyl ester 
• 71858-91-8 2-(5-methyl-[2]pyridyl)-ethanol 
• 350-46-9 4-Fluoronitrobenzene 
• 1317-39-1 copper(I) oxide 
• 85583-51-3 4-[2-(5-methyl-pyridin-2-yl)ethoxy]nitrobenzene 

Downstream Products

• 105355-32-6 2-imino-5-{4-[2-(5-methyl-pyridin-2-yl)ethoxy]benzyl}-4-thiazolidinone 
• 105355-35-9 5-[4-[2-(5-methyl-2-pyridyl)ethoxy]benzyl]-2,4-thiazolidinedione 
• 101931-06-0 5-{4-[2-Hydroxy-2-(5-methyl-pyridin-2-yl)ethoxy]benzyl}-2,4-thiazolidinedione 
• 101966-21-6 methyl 3-{4-[2-acetoxy-2-(5-methyl-pyridin-2-yl)ethoxy]phenyl}-2-bromopropionate 

Relevant academic research and scientific papers

Studies on antidiabetic agents. Synthesis and hypoglycemic activity of 5-[4-(pyridylalkoxy)benzyl]-2,4-thiazolidinediones

The synthesis of a series of 5-[4-(pyridylalkoxy)benzyl]-2,4-thiazolidinediones is described. These compounds were evaluated for hypoglycemic and hypolipidemic activities in genetically obese and diabetic mice, yellow KK. 2-(2-Pyridyl)alkoxy derivatives were found to have much better hypoglycemic and hypolipidemic activities than 2-(3-pyridyl)- and 2-(4-pyridyl)alkoxy derivatives or even the previously reported compound, ciglitazone. The introduction of a hydroxyl group at the 2-position of the ethoxy chain potentiated the activities. Among the potent compounds, pioglitazone (AD-4833) was selected as a candidate compound.

Thiazolidinedione derivatives, useful as antidiabetic agents

Thiazolidinedione derivatives of the formula: STR1 and pharmacologically acceptable salts thereof are novel compounds, which exhibit in mammals blood sugar- and lipid-lowering activity, and are of value as a therapeutic agent for treatment of diabetes and hyperlipemia.